Snapshot from Jul 19, 2026 at 14:14 UTC. For live data and tracking: View Live
Events / Business / Kuehn Law Investigates Corcept Therapeutics
Business shareholder lawsuit

Kuehn Law Investigates Corcept Therapeutics

Analysis based on 6 articles · First reported Jun 17, 2026 · Last updated Jun 25, 2026

Sentiment
-50
Attention
4
Articles
6
Market Impact
General
Live prominence charts, article sentiment distribution, and event development timeline available on the Ergen Dashboard
Market Impact

The market is negatively impacted by the news of a potential lawsuit against Knight Therapeutics, as it raises concerns about the company's transparency and the future of its drug candidate, relacorilant. This could lead to a decrease in Knight Therapeutics's stock price and investor confidence in the pharmaceutical sector.

Pharmaceuticals Legal Services
Event Summary

Kuehn Law, a shareholder litigation law firm, is investigating Knight Therapeutics for allegedly breaching its fiduciary duties to shareholders. The investigation stems from a federal securities lawsuit claiming that Knight Therapeutics failed to disclose concerns from the United States — Food and Drug Administration regarding the adequacy of its clinical development program for relacorilant, a new product candidate. The lawsuit suggests that the New Drug Application for relacorilant faces a material risk of rejection, despite Knight Therapeutics having previously touted its expected success. Kuehn Law is encouraging shareholders who purchased Knight Therapeutics stock prior to October 31, 2024, to contact them to enforce their rights.

Entities Involved
stock
Knight Therapeutics
Knight Therapeutics is facing a federal securities lawsuit for allegedly failing to disclose concerns from the FDA regarding its drug candidate, relacorilant, which could lead to a rejection of its New Drug Application. This event negatively impacts its stock price and reputation.
Importance 100.0 Sentiment -70.0
govactor
United States — Food and Drug Administration
The United States — Food and Drug Administration expressed concerns to Knight Therapeutics about the adequacy of its clinical development program for relacorilant, which is a key factor in the lawsuit against Knight Therapeutics.
Importance 60.0 Sentiment 0.0
per
Justin Kuehn
Justin Kuehn, an attorney at Kuehn Law, is leading the investigation into Knight Therapeutics and is a contact for affected shareholders.
Importance 50.0 Sentiment 10.0
per
Sophia Anne Silayan
Sophia Anne Silayan is a contact person for investors interested in the lawsuit against Knight Therapeutics.
Importance 30.0 Sentiment 10.0
Relationships
Knight Therapeutics related ↔ United States — Food and Drug Administration
Justin Kuehn related ↔ Sophia Anne Silayan
ERGEN INTELLIGENCE
Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.